PDCD1 and hepatocellular carcinoma: There has also been a rapid rise in the amount of immunotherapy clinical trials in HCC in the past 15 years.12, 13, 14 Among these trials, immune checkpoint (PD1/PDL1 and CTLA‐4) blockade therapy has received great acclaim.